Prospects for the control of host defenses.

Important note: Information in this article was accurate in 1982. The state of the art may have changed since the publication date.

Prospects for the control of host defenses.

Surgery. 1982 Aug;92(2):138-45. Unique Identifier : AIDSLINE MED/82250417
Howard RJ

Abstract: Systemic host defenses include phagocytic cells (neutrophils and macrophages), humoral immunity, and cell-mediated immunity. It may be beneficial to increase host defenses to prevent and treat infections, cancer, and often acquired or systemic immunodeficiency disorders. On the other hand, inhibition of immune responsiveness is desirable to prevent and treat rejection of organ grafts, allergic reactions, and autoimmune diseases. There are three general ways to modulate host defenses--pharmacologic agents, radiation, and biologic manipulation. The first two have been most widely applied but lack specificity. Thus, they generally inhibit a variety of immune responses that can lead to undesirable side effects such as infections and cancer. Nonspecificity is generally desirable in stimulating neutrophils and macrophages because it may not be known which bacterium is causing the infection or because several may be involved. Biologic manipulations have the advantage of great specificity but are much more difficult to apply to humans. Some of these types of manipulations that seem to hold promise are stimulators of phagocytosis, immunologic tolerance, control of specific subsets of T lymphocytes, monoclonal antibodies, and interferon. Immune modulation has a price-cancer, susceptibility to infection, toxicity of drugs, serum sickness, anaphylactic reactions, Arthus reaction, and disseminated infection with live viral vaccines.

Keywords: Animal Antibodies, Monoclonal/IMMUNOLOGY Cyclosporins/THERAPEUTIC USE Histocompatibility Antigens Class II/IMMUNOLOGY Human HLA Antigens/IMMUNOLOGY Immune Tolerance *Immunization/ADVERSE EFFECTS *Immunosuppression Immunosuppressive Agents/THERAPEUTIC USE Immunotherapy/ADVERSE EFFECTS Interferons/IMMUNOLOGY/THERAPEUTIC USE Phagocytosis Radiotherapy T-Lymphocytes/IMMUNOLOGY Transplantation Immunology Vaccines JOURNAL ARTICLE

821130
M82B0009

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1982. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1982. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .